LiMM Therapeutics
LiMM Therapeutics is a Paris-based preclinical biopharmaceutical company founded in 2017 that develops therapeutics targeting molecular cross-talk between neuronal and innate lymphoid cells for immune-mediated diseases.
- Company typePrivate
- Founded2017
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
LiMM Therapeutics firmographics
Firmographics- Name
- LiMM Therapeutics
- Website
- https://limmtx.com
- Company type
- Private
- Founded year
- 2017
- Headcount range
- 11–50 employees
- Short description
- LiMM Therapeutics is a Paris-based preclinical biopharmaceutical company founded in 2017 that develops therapeutics targeting molecular cross-talk between neuronal and innate lymphoid cells for immune-mediated diseases.
- Ownership category
- akta.pro rank
LiMM Therapeutics industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where LiMM Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Markets served
LiMM Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
LiMM Therapeutics product offering
Product offeringCore offering
LiMM Therapeutics is a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells to develop novel therapeutics. The company's work targets neuro-immune interactions for the treatment of inflammatory and immune-related diseases, operating in the early-stage research and drug discovery domain.
Differentiator
Problem solved
Functional benefit
Companies that use LiMM Therapeutics
Customer profileIdeal customer profiles1 record
LiMM Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
LiMM Therapeutics competitors and assessment
Company assessmentDirect peers
- INmune Bio: INmune Bio focuses on innate immune modulation to treat neurodegenerative and neuroinflammatory diseases. Its mechanism emphasis on innate immunity parallels LiMM's innate lymphoid cell approach in CNS indications.
- Alector: Alector develops immuno-neurology therapies targeting neurodegenerative diseases by modulating microglial and innate immune function in the brain. It is the closest publicly listed peer to LiMM's neuronal-immune mechanism thesis.
- reMYND: reMYND develops therapeutics targeting neurodegeneration, including Alzheimer's and Parkinson's, with an emphasis on restoring neuronal protein homeostasis. It is comparable as a European early-stage CNS-focused biotech.
- Confo Therapeutics: Confo Therapeutics is a Belgian biotech developing GPCR-targeting therapeutics for CNS and metabolic disorders. It is comparable as a European early-stage CNS biopharma with mechanistic differentiation.
- Cortexyme: Cortexyme develops therapeutics targeting innate immune pathways in the brain for Alzheimer's disease and other neurodegenerative conditions. It is comparable as a CNS-focused biotech leveraging immune-system biology.
Broad incumbents
- Theravance Biopharma: Theravance Biopharma develops therapeutics including CNS and immunology programs. It is comparable as a biopharma with CNS pipeline presence and broader immunology expertise relevant to LiMM's innate-immune CNS approach.
- Ipsen: Ipsen is a major French specialty pharmaceutical company with a meaningful neuroscience and neurotoxin franchise. It is comparable as an established Paris-based pharma that anchors the local CNS commercial ecosystem.
Regional players
- GenSight Biologics: GenSight Biologics is a Paris-based clinical-stage biotech developing gene therapies for CNS and ophthalmologic neurodegenerative diseases. It is comparable as a French preclinical/early-clinical CNS therapeutics peer.
Emerging players
- LAVA Therapeutics: LAVA Therapeutics engineers innate-like gamma-delta T cells and bispecific antibodies for cancer and immunology. Its focus on innate lymphoid lineage biology overlaps conceptually with LiMM's ILC mechanism, though its indication focus is oncology.
- Egle Therapeutics: Egle Therapeutics is a Paris-based immuno-oncology biotech focused on regulatory T cells and immune biology. It is comparable as a French early-stage biotech built around novel lymphoid immune cell biology.
Market position
Customer concentration
LiMM Therapeutics social profiles
Digital presenceLiMM Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
LiMM Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
LiMM Therapeutics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LiMM Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LiMM Therapeutics
What does LiMM Therapeutics do?
LiMM Therapeutics is a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells to develop novel therapeutics. The company's work targets neuro-immune interactions for the treatment of inflammatory and immune-related diseases, operating in the early-stage research and drug discovery domain.
When was LiMM Therapeutics founded?
LiMM Therapeutics was founded in 2017. It employs 11 to 50 people.
Where is LiMM Therapeutics based?
LiMM Therapeutics is headquartered in Paris, France, in the Europe region.
Who are LiMM Therapeutics's main competitors?
Direct peers on record are INmune Bio, Alector, reMYND, Confo Therapeutics and Cortexyme. Broad incumbents are Theravance Biopharma and Ipsen. GenSight Biologics is listed as a regional player. Emerging players are LAVA Therapeutics and Egle Therapeutics.
Does LiMM Therapeutics have an API?
No public API is recorded for LiMM Therapeutics.
What industry is LiMM Therapeutics in?
LiMM Therapeutics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.